tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ATOS Stock Latest News

Atossa Therapeutics: Strategic Advancements in Breast Cancer Treatment Drive Buy Rating
RatingsAtossa Therapeutics: Strategic Advancements in Breast Cancer Treatment Drive Buy Rating
7d ago
ATOS
Atossa Therapeutics Reports Increased Q3 Losses Amid R&D Focus
PremiumCompany Announcements
Atossa Therapeutics Reports Increased Q3 Losses Amid R&D Focus
8d ago
ATOS
Atossa Therapeutics: Advancements in Z-endoxifen Development and Strategic Leadership Enhancements Drive Buy Rating
PremiumRatings
Atossa Therapeutics: Advancements in Z-endoxifen Development and Strategic Leadership Enhancements Drive Buy Rating
8d ago
ATOS
Atossa Therapeutics reports Q3 EPS (7c), consensus (7c)
PremiumThe Fly
Atossa Therapeutics reports Q3 EPS (7c), consensus (7c)
8d ago
ATOS
Atossa Therapeutics Advances Breast Cancer Treatment with (Z)-Endoxifen Study
PremiumCompany Announcements
Atossa Therapeutics Advances Breast Cancer Treatment with (Z)-Endoxifen Study
24d ago
ATOS
Atossa Therapeutics Appoints New Chief Financial Officer
PremiumCompany AnnouncementsAtossa Therapeutics Appoints New Chief Financial Officer
1M ago
8K
ATOS
Atossa Therapeutics appoints Mark Daniel as CFO
Premium
The Fly
Atossa Therapeutics appoints Mark Daniel as CFO
1M ago
ATOS
Atossa Therapeutics advances global patent strategy for Z-Endoxifen
Premium
The Fly
Atossa Therapeutics advances global patent strategy for Z-Endoxifen
1M ago
ATOS
Atossa Therapeutics management to meet virtually with Craig-Hallum
PremiumThe Fly
Atossa Therapeutics management to meet virtually with Craig-Hallum
1M ago
ATOS
Strategic Adjustments and Promising Data Bolster Atossa Therapeutics’ Buy Rating
PremiumRatings
Strategic Adjustments and Promising Data Bolster Atossa Therapeutics’ Buy Rating
1M ago
ATOS
Promising Potential of Atossa Therapeutics’ Endoxifen in Metastatic Breast Cancer Treatment
PremiumRatings
Promising Potential of Atossa Therapeutics’ Endoxifen in Metastatic Breast Cancer Treatment
2M ago
ATOS
Atossa Therapeutics Releases Updated Corporate Presentation
PremiumCompany Announcements
Atossa Therapeutics Releases Updated Corporate Presentation
2M ago
8K
ATOS
Atossa Therapeutics: Strategic Advancements and Strong Financial Position Signal Promising Future
PremiumRatingsAtossa Therapeutics: Strategic Advancements and Strong Financial Position Signal Promising Future
2M ago
ATOS
Atossa Therapeutics appoints CORE IR for investor relations
Premium
The Fly
Atossa Therapeutics appoints CORE IR for investor relations
2M ago
ATOS
Buy Rating Supported by Atossa Therapeutics’ Strategic Advancements in Z-endoxifen Development for Breast Cancer Treatment
Premium
Ratings
Buy Rating Supported by Atossa Therapeutics’ Strategic Advancements in Z-endoxifen Development for Breast Cancer Treatment
2M ago
ATOS
Atossa Therapeutics Announces New Regulatory Strategy
PremiumCompany Announcements
Atossa Therapeutics Announces New Regulatory Strategy
2M ago
8K
ATOS
Atossa Therapeutics has requested Type C meeting with U.S. FDA
PremiumThe Fly
Atossa Therapeutics has requested Type C meeting with U.S. FDA
2M ago
ATOS
Atossa Therapeutics Receives Nasdaq Non-Compliance Notice
PremiumCompany Announcements
Atossa Therapeutics Receives Nasdaq Non-Compliance Notice
3M ago
8K
ATOS
Atossa selects PSI for Z-endoxifen monotherapy study
PremiumThe Fly
Atossa selects PSI for Z-endoxifen monotherapy study
3M ago
ATOS
Buy Rating for Atossa Therapeutics: Strong Financials and Promising Endoxifen Developments
PremiumRatingsBuy Rating for Atossa Therapeutics: Strong Financials and Promising Endoxifen Developments
3M ago
ATOS
Atossa Therapeutics Advances Breast Cancer Treatments
Premium
Company Announcements
Atossa Therapeutics Advances Breast Cancer Treatments
3M ago
ATOS
Positive FDA Feedback and Promising Phase 2 Results Justify Buy Rating for Atossa Therapeutics
Premium
Ratings
Positive FDA Feedback and Promising Phase 2 Results Justify Buy Rating for Atossa Therapeutics
3M ago
ATOS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >